Pyelonephritis in pregnancy. How adequate is empirical treatment?;Pielonefritis en el embarazo. ¿Hasta qué punto es adecuado el tratamiento empírico?

Revista Espanola de Quimioterapia

Volumn 26, Issue 1, 2013, Pages 30-33

  Artero, Arturo ^a   Alberola, Juan ^a   Eiros, José María ^b   Nogueira, José Miguel ^a   Cano, Antonio ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Empirical treatment; Pregnancy; Pyelonephritis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN;

ACUTE PYELONEPHRITIS; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; HOSPITAL ADMISSION; HUMAN; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME VARIABLE; PREGNANT WOMAN; PROTEUS MIRABILIS; URINARY TRACT INFECTION; URINE CULTURE;

ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMORBIDITY; ESCHERICHIA COLI INFECTIONS; FEMALE; FOSFOMYCIN; HOSPITALS, UNIVERSITY; HUMANS; INAPPROPRIATE PRESCRIBING; MICROBIAL SENSITIVITY TESTS; OBSTETRICS AND GYNECOLOGY DEPARTMENT, HOSPITAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYELONEPHRITIS; RECURRENCE; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877783430     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gilstrap LC, Ramin SM. Urinary tract infections during pregnancy. Obstet Gynecol Clin North Am 2001; 28:581-91.
2. Macejko AM, Schaeffer AJ. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. Urol Clin North Am 2007; 34:35-42.
3. Smaill F, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev 2007 Apr 18; (2): CD000490.
4. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40:643-54.
5. Nowicki B, Sledzinska A, Samet A, Nowick S. Pathogenesis of gestational urinary tract infection: urinary obstruction versus immune adaptation and microbial virulence. BJOG 2011; 118:109-12.
6. Jamie WE, Edwards RK, Duff P. Antimicrobial susceptibility of Gram-negative uropathogens isolated from obstetric patients. Infect Dis Obstet Gynecol 2002; 10:123-26.
7. Greer LG, Roberts SW, Sheffield SJS, Rogers VL, Hill JB, Mcintire DD, et al. Ampicillin Resistance and Outcome Differences Microorganisms Antibiotic resistance (%) Ampicillin Amox-Clav1 CefuroximeCefotaximeGentamicin TMP-SMX2 Fosfomycin Escherichia coli (n=35) 49 14 6 3 3 11 3 Other microorganisms (n=15) 67 20 27 27 27 20 13 TOTAL (n=50) 54 16 12 10 10 14 6 Table 2 Aetiology and proportion of antibiotic resistance in 50 pregnant women with acute pyelonephritis admitted to the hospital. 1Amoxicillin-clavulanate, 2Trimethoprim-sulfamethoxazole. Quinolones are excluded because they are not recommended for pregnant women. in Acute Antepartum Pyelonephritis. Infect Dis Obstet Gynecol 2008; 2008:891426.
8. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate Antimicrobial Treatment of Infections. A Risk Factor for Hospital Mortality Among Critically Ill Patients. Chest 1999; 115: 462-74.
9. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropiate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115: 529-35.
10. Ibrahim EH; Sherman G, Wards S, Frase VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patients outcomes in the ICU setting. Chest 2000; 118: 146-55.
11. Jolley JA, Wing DA. Pyelonephritis in Pregnancy An Update on Treatment Options for Optimal Outcomes. Drugs 2010; 70:1643-55.
12. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum β-lactamase- producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011; 39:333-40.
13. Pitout JD, Laupland KB. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159-66.
14. Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P. Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs 2009; 10:172-80.
15. Gupta K, Hooton TM, Naber K G, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:103-20.
16. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43-50.